CA2366062A1 - Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations - Google Patents

Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations Download PDF

Info

Publication number
CA2366062A1
CA2366062A1 CA002366062A CA2366062A CA2366062A1 CA 2366062 A1 CA2366062 A1 CA 2366062A1 CA 002366062 A CA002366062 A CA 002366062A CA 2366062 A CA2366062 A CA 2366062A CA 2366062 A1 CA2366062 A1 CA 2366062A1
Authority
CA
Canada
Prior art keywords
seq
dkk
atcc
accession number
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002366062A
Other languages
English (en)
Other versions
CA2366062C (fr
Inventor
Sean Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366062A1 publication Critical patent/CA2366062A1/fr
Application granted granted Critical
Publication of CA2366062C publication Critical patent/CA2366062C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux polypeptides, de nouvelles protéines et de nouvelles molécules d'acide nucléique Dkk et associées à Dkk. En plus de protéines Dkk et associées à Dkk isolées et complètes, l'invention concerne également des protéines de fusion isolées, des peptides antigéniques et des anticorps. L'invention concerne en outre des molécules d'acide nucléique Dkk et associées à Dkk, des vecteurs d'expression recombinants contenant une molécule d'acide nucléique de la présente invention, des cellules hôtes dans lesquelles on a introduit lesdits vecteurs d'expression et des animaux transgéniques non humains dans lesquels un gène Dkk ou associé à Dkk a été introduit ou dissocié. L'invention concerne par ailleurs des méthodes diagnostiques, thérapeutiques et de criblage qui utilisent les compositions de la présente invention.
CA2366062A 1999-03-05 2000-03-03 Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations Expired - Lifetime CA2366062C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26302299A 1999-03-05 1999-03-05
US09/263,022 1999-03-05
PCT/US2000/005452 WO2000052047A2 (fr) 1999-03-05 2000-03-03 Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2366062A1 true CA2366062A1 (fr) 2000-09-08
CA2366062C CA2366062C (fr) 2014-06-17

Family

ID=23000057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2366062A Expired - Lifetime CA2366062C (fr) 1999-03-05 2000-03-03 Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations

Country Status (4)

Country Link
EP (1) EP1161445A2 (fr)
AU (1) AU3510200A (fr)
CA (1) CA2366062C (fr)
WO (1) WO2000052047A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255229T1 (de) * 2000-02-24 2003-12-15 Oxford Glycosciences Uk Ltd Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
EP1222933A1 (fr) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt
HUP0303194A2 (hu) * 2001-02-16 2003-12-29 Genentech, Inc. DKK-1 és antagonistái alkalmazásai
EP1573024A4 (fr) 2001-04-10 2007-08-29 Agensys Inc Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
EP1395285A4 (fr) * 2001-05-17 2005-06-01 Genome Therapeutics Corp Reactifs et procedes destines a moduler des interactions induites par dkk
ES2304210B1 (es) * 2002-10-15 2009-09-28 Genentech, Inc Utilizacion de dkk-5, procedimiento y equipo de diagnostico de trastornos resistentes a la insulina e hibridoma y anticuerpo contra dkk-5.
US7811750B2 (en) * 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
US8124087B2 (en) 2002-12-05 2012-02-28 Board Of Trustees Of The University Of Arkansas Methods of controlling bone loss by inhibiting DKK1
MXPA05006033A (es) * 2002-12-05 2006-03-08 Univ Arkansas Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos.
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
US7622553B2 (en) 2003-11-17 2009-11-24 Merck & Co., Inc. Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof
US7473770B2 (en) 2003-11-17 2009-01-06 Merck & Co., Inc. Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof
US8343922B2 (en) * 2004-05-19 2013-01-01 Enzo Biochem, Inc. Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
WO2006010534A1 (fr) * 2004-07-28 2006-02-02 F.Hoffmann-La Roche Ag Dickkopf 3 en tant que cible / marqueur de la defaillance des cellules beta
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
US8252267B2 (en) 2005-03-30 2012-08-28 Sagres Discovery, Inc. DKKL-1 splice product modulators for cancer diagnosis and therapy
WO2007104181A1 (fr) * 2006-03-13 2007-09-20 Shanghai Cancer Institute Utilisations de la protéine dkk-1 dans le diagnostic de cancers
CN103080309B (zh) * 2010-07-01 2015-11-25 国立大学法人冈山大学 REIC/Dkk-3蛋白的部分区域多肽
KR20130021315A (ko) * 2011-08-22 2013-03-05 인하대학교 산학협력단 Ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
WO2020261100A1 (fr) * 2019-06-25 2020-12-30 Friedrich Miescher Institute For Biomedical Research Promoteur pour l'expression spécifique de gènes dans des cellules exprimant une protéine acide fibrillaire gliale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027932A2 (fr) * 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Proteine specifique du cervelet et de l'embryon
DE69842225D1 (de) * 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
DE19844293C2 (de) * 1998-09-18 2002-03-14 B & S Elektronische Geraete Gm Beleuchtungseinrichtung

Also Published As

Publication number Publication date
EP1161445A2 (fr) 2001-12-12
WO2000052047A9 (fr) 2002-03-14
WO2000052047A3 (fr) 2001-02-01
WO2000052047A2 (fr) 2000-09-08
AU3510200A (en) 2000-09-21
CA2366062C (fr) 2014-06-17

Similar Documents

Publication Publication Date Title
US8202966B2 (en) Human Dickkopf-related protein and nucleic acid molecules and uses therefor
CA2366062C (fr) Proteine humaine et molecules d'acide nucleique associees a dickkopf et leurs utilisations
US20100093056A1 (en) Antibodies that bind dkk-related proteins
AU7137398A (en) Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
US5942420A (en) Molecules of the follistatin-related protein family and uses therefor
CA2292899A1 (fr) Element ntn-2 de la famille des ligands du tnf
MXPA01002461A (es) Genes inducidos por leptin.
CA2351365A1 (fr) Proteines d'interaction de canaux potassiques (pcip) et procedes de leur utilisation
AU784993B2 (en) CRSP protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
AU2013200856A1 (en) CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses thereof
AU2010236081A1 (en) CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses therefor

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200303